{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+Abatacept", "query": { "intervention": "Subcutaneous Abatacept" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 48, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+Abatacept&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T05:05:46.248Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02915159", "title": "A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sjogrens Disease" ], "interventions": [ { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2016-12-06", "completion_date": "2019-07-23", "has_results": true, "last_update_posted_date": "2020-08-10", "last_synced_at": "2026-09-13T05:05:46.248Z", "location_count": 19, "location_summary": "Fullerton, California • Riverside, California • Lakewood, Colorado + 14 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Lawrenceville", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT02915159" }, { "nct_id": "NCT02429934", "title": "Abatacept for SLE Arthritis (IM101-330)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus Arthritis" ], "interventions": [ { "name": "abatacept also known as Orencia also known as CTLA4-Ig", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2015-10", "completion_date": "2019-09-01", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-09-13T05:05:46.248Z", "location_count": 2, "location_summary": "Los Angeles, California • San Diego, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02429934" }, { "nct_id": "NCT06307301", "title": "Study in ALS With Abatacept & IL-2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "Abatacept Injection [Orencia] and Proleukin (aldesleukin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2021-10-28", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-13T05:05:46.248Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06307301" }, { "nct_id": "NCT03929601", "title": "Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Rituximab-pvvr", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Sterile Sodium Chloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "8 Years to 45 Years" }, "enrollment_count": 74, "start_date": "2023-10-30", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-13T05:05:46.248Z", "location_count": 17, "location_summary": "Orange, California • Palo Alto, California • San Francisco, California + 14 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03929601" }, { "nct_id": "NCT01717846", "title": "Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Apoptotic DNA Damage", "Rheumatoid Arthritis", "T-cell Lymphocytosis" ], "interventions": [ { "name": "Group 1 or Orencia treated group", "type": "DRUG" }, { "name": "Group 2 (DMARDS treated group)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 0, "start_date": "2012-12", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2016-05-11", "last_synced_at": "2026-09-13T05:05:46.248Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01717846" }, { "nct_id": "NCT04118153", "title": "Early Markers of Disease and Response to Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sandra Lord, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "6 Years to 55 Years" }, "enrollment_count": 60, "start_date": "2021-03-05", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-09-13T05:05:46.248Z", "location_count": 2, "location_summary": "Seattle, Washington • Milwaukee, Wisconsin", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04118153" }, { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-12-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-13T05:05:46.248Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" }, { "nct_id": "NCT00663702", "title": "Phase IIIB Switching From Intravenous to Subcutaneous Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2008-05", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2015-03-09", "last_synced_at": "2026-09-13T05:05:46.248Z", "location_count": 18, "location_summary": "Huntsville, Alabama • La Jolla, California • Long Beach, California + 15 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00663702" }, { "nct_id": "NCT05782335", "title": "Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [], "intervention_types": [], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-11-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-13T05:05:46.248Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05782335" }, { "nct_id": "NCT03882008", "title": "A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2019-05-23", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-09-13T05:05:46.248Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03882008" } ] }